(CNN)Eisai Co. will withdraw its weight reduction drug Belviq after the United States Food and Drug Administration stated medical trials revealed an increased occurrence of cancer amongst users , the business stated.
The FDA revealed last month it was examining trial outcomes on the prescription drug, likewise referred to as lorcaserin, an oral medication for overweight grownups, since of prospective cancer dangers. The company Thursday asked individuals to stop taking the drug.
The “possible threat of cancer connected with the drug surpasses the advantage of treatment,” Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, stated in a declaration.
The company stated in a different press release that medical trials revealed lorcaserin increased the danger of a variety of cancers, consisting of pancreatic, colorectal and lung.
“As kept in mind in a brand-new Drug Safety Communication provided today, clients ought to stop utilizing the medication Belviq and Belviq XR(lorcaserin)and speak with their healthcare specialists about other treatment choices for weight-loss,”Woodcock stated, including that medical professionals need to stop recommending the drugs.
The FDA is not advising any unique cancer screenings for individuals who are presently taking the drug or might have in the past.
The FDA authorized lorcaserin in 2012 and made the medication offered the list below year, however continued scientific trials on the drug to examine cardiovascular threats. Rather, it discovered an increased cancer threat.
